Global Drug Delivery Partnering Deals Terms and Agreements 2015-2022

5 min readPublished On: June 14th, 2022By

Dublin – The “Global Drug Delivery Partnering Terms and Agreements 2015-2022” report has been added to’s offering.

The Global Drug Delivery Partnering Terms and Agreements 2015-2022 report provides comprehensive understanding and unprecedented access to the Drug Delivery partnering deals and agreements entered into by the worlds leading healthcare companies.

One of the key highlights of the report is that over 1500 online deal records of actual Drug Delivery deals, as disclosed by the deal parties, are included towards the end of the report in a directory format – by company A-Z, stage of development, deal type, therapy focus, and technology type – that is easy to reference. Each deal record in the report links via Weblink to an online version of the deal.

The report takes the reader through a comprehensive review Drug Delivery deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering Drug Delivery partnering deals.

The report presents financial deal term values for Drug Delivery deals, listing by headline value, upfront payments, milestone payments and royalties, enabling readers to analyse and benchmark the financial value of deals.

The middle section of the report explores the leading dealmakers in the Drug Delivery partnering field; both the leading deal values and most active Drug Delivery dealmaker companies are reported allowing the reader to see who is succeeding in this dynamic dealmaking market.

In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Whilst many companies will be seeking details of the payment clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.

A comprehensive series of appendices is provided organized by Drug Delivery partnering company A-Z, stage of development, deal type, and therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Drug Delivery technologies and products.

Key benefits

Global Drug Delivery Partnering Terms and Agreements 2015-2022 provides the reader with the following key benefits:

  • In-depth understanding of Drug Delivery deal trends since 2015
  • Access to headline, upfront, milestone and royalty data
  • Detailed access to actual Drug Delivery contracts entered into by leading biopharma companies
  • Identify most active Drug Delivery dealmakers since 2015
  • Insight into terms included in a Drug Delivery partnering agreement, with real world examples
  • Understand the key deal terms companies have agreed in previous deals
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

In Global Drug Delivery Partnering Terms and Agreements 2015-2022, the available deals are listed by:

  • Company A-Z
  • Headline value
  • Stage of development at signing
  • Deal component type
  • Specific therapy target
  • Technology type

Analyzing actual contract agreements allows assessment of the following:

  • What are the precise rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How are sales and payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Key Topics Covered:

Executive Summary

Chapter 1 – Introduction

Chapter 2 – Trends in Drug Delivery dealmaking
2.1. Introduction
2.2. Drug Delivery partnering over the years
2.3. Most active Drug Delivery dealmakers
2.4. Drug Delivery partnering by deal type
2.5. Drug Delivery partnering by therapy area
2.6. Deal terms for Drug Delivery partnering
2.6.1 Drug Delivery partnering headline values
2.6.2 Drug Delivery deal upfront payments
2.6.3 Drug Delivery deal milestone payments
2.6.4 Drug Delivery royalty rates

Chapter 3 – Leading Drug Delivery deals
3.1. Introduction
3.2. Top Drug Delivery deals by value

Chapter 4 – Most active Drug Delivery dealmakers
4.1. Introduction
4.2. Most active Drug Delivery dealmakers
4.3. Most active Drug Delivery partnering company profiles

Chapter 5 – Drug Delivery contracts dealmaking directory
5.1. Introduction
5.2. Drug Delivery contracts dealmaking directory

Chapter 6 – Drug Delivery dealmaking by technology type


Appendix 1 – Drug Delivery deals by company A-Z

Appendix 2 – Drug Delivery deals by stage of development

  • Discovery
  • Preclinical
  • Phase I
  • Phase II
  • Phase III
  • Regulatory
  • Marketed
  • Formulation

Appendix 3 – Drug Delivery deals by deal type

  • Asset purchase
  • Assignment
  • Bigpharma outlicensing
  • Co-development
  • Collaborative R&D
  • Co-market
  • Co-promotion
  • Cross-licensing
  • Development
  • Distribution
  • Equity purchase
  • Evaluation
  • Grant
  • Joint venture
  • Licensing
  • Litigation
  • Manufacturing
  • Marketing
  • Material transfer
  • Option
  • Promotion
  • Research
  • Settlement
  • Spin out
  • Sub-license
  • Supply
  • Technology transfer
  • Termination
  • Warranty

Appendix 4 – Drug Delivery deals by therapy area

Appendix 5 – Deal type definitions

Appendix 6 – Further reading on dealmaking

Companies Mentioned

  • Delta 9 Cannabis
  • Korea Advanced Institute of Science and Technology
  • STADA Arzneimittel
  • TFB & Associates
  • Imbed Bio
  • Sesen Bio
  • Motif Bio
  • Avior Bio
  • Tetra Bio-Pharma
  • Helix BioPharma
  • Carna BioSciences
  • AMPEL BioSolutions
  • Leads Biolabs
  • Orbit Biomedical
  • Proxy Biomedical
  • Dance Biopharm
  • NEMUS Bioscience
  • Artes Biotechnology
  • Tamir Biotechnology
  • Juyou Biotechnology
  • Small Business Innovation Research
  • Auxly Cannabis Group
  • North Carolina State University
  • Magle Chemoswed
  • LatAm Clinical Trials
  • Eve & Co
  • Aceto Corporation
  • Green Cross LabCell
  • Nitto Denko
  • Kwang Dong Pharmaceutical
  • Rapid Dose Therapeutics
  • Fidia Farmaceutici
  • Apsen Farmacutica
  • Grupo Ferrer
  • Altus Formulation
  • Aspen Global
  • Eitan Group
  • Clear Guide Medical
  • Evero Health
  • World Health Organization
  • Bayer Healthcare

(This information is primarily sourced from Research and Markets.  Highly Capitalized has neither approved nor disapproved the contents of this news release. Read our Disclaimer here).


About the Author: News Team

Newsteam at Highly Capitalized are some of the most experienced writers in cannabis and psychedelics business & finance. We cover capital markets, finance, branding, marketing and everything important in between. Most of all, we follow the money.

Share This Story, Choose Your Platform!

Latest News